Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline and α-tocopherol for Pneumonitis Prevention in Stage III NSCLC
NCT06634056Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- Jun 2026
- Primary completion
- Nov 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pentoxifylline and alpha-tocopherol in radiation-induced lung injury (RILI) (2 arms), sponsored by University Health Network. Primary endpoint: Change in risk of Lung Injury at 1 year. Started Jun 2026; status: recruiting.
02
Drugs
pentoxifyllinealpha-tocopherol
03
Conditions
radiation-induced lung injury (RILI)
Beyond the preview
Go deeper on NCT06634056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06634056.